Latest Posts

PathGroup has discontinued the Resin T3 Uptake Ratio test (Test Code: RT3R) and has replaced it with the T3 Uptake test (Test Code: T3U).

Click here for more information.

Effective June 10, 2019, PathGroup has introduced a new automated and semi-quantitative optical measurement system from Roche Diagnostics for the assessment of elevated triglycerides (lipemia), hemoglobin (hemolysis) and bilirubin (icterus) in human serum and plasma specimens.  The new procedure will replace the historical subjective visual inspection procedure for marked elevations in these interfering substances.   This new procedure will be performed on all plasma and serum specimens with conventional clinical chemistry and immunochemistry tests performed on the Roche analyzers. Please note that serum indices testing is independent from the assessment of unspun or partially spun specimens.

Click here to learn more.

Effective June 24, 2019, PathGroup will begin calculating estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation instead of the previously utilized Modification of Diet in Renal Disease (MDRD) equation.  eGFR values are derived from patient specific factors including, serum creatinine, age, gender, and race and are used to assess the kidney’s filtering capacity.  While both equations are accurate below 60 mL/min/1/73 m2, the CKD-EPI equation provides a more accurate value above this threshold.  This change will allow PathGroup to report numeric eGFR values for results greater than 60 mL/min/1.73 m².

Click here to learn more.

On February 10, 2019, PathGroup introduced new automated clinical chemistry instrumentation manufactured by Roche Diagnostics.   At that time, our reported reference ranges were based on Roche FDA cleared or approved product labeling and as validated in correlation studies performed at PathGroup.

Click here to read more.

Effective February 10, 2019, PathGroup is pleased to announce the introduction of new testing equipment and methods for serum and plasma based general chemistry and immunoassay tests manufactured by the market leader in global clinical testing, Roche Diagnostics.

To read more, click here.

Effective 3/4/2019

In late 2018, the FDA approved Vitrakvi® (larotrectinib) for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity and have no satisfactory alternative treatments or that have progressed following treatment.

PathGroup is pleased to announce the availability of Pan-TRK IHC (EPR17341) for this new indication. Orders within the SmartGenomics family of profiles will have TRK added based on the clinical context of the patient. The antibody is also available as a stand-alone immunohistochemistry test.

Click here for more information.

On February 10, 2019, PathGroup introduced new automated clinical chemistry instrumentation manufactured by Roche Diagnostics. At that time, our reported reference ranges were based on Roche FDA cleared or approved product labeling and as validated in correlation studies performed at PathGroup.  Effective February 27 – 28, 2019, we have slightly modified the following test reference ranges in accordance with statistical analysis with our actual patient population.

For more information, click here.

Effective January 14, 2019, PathGroup is pleased to introduce new LC/MS/MS methodology for the confirmation of urine opiates (Morphine, Oxymorphone, Hydromorphone, Codeine, Noroxycodone, Oxycodone, Hydrocodone, Norhydrocodone, and 6-Acetylmorphine).

For more information, click here.

Effective January 1, 2019, there will be CPT code changes for pathology and laboratory testing services provided by PathGroup.

For more information, CLICK HERE.

Effective March 29, 2018, PathGroup will perform testing for Hepatitis B Virus via Quantitative Real-Time PCR.

For more information, CLICK HERE